CRISPR Therapeutics AG (NASDAQ:CRSP) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||60||0.00||34.37M||-0.46||0.00|
|Cyclacel Pharmaceuticals Inc.||N/A||0.00||12.05M||-0.53||0.00|
Table 1 highlights CRISPR Therapeutics AG and Cyclacel Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.
Table 2 has CRISPR Therapeutics AG and Cyclacel Pharmaceuticals Inc.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,235,636.97%||-2.6%||-2%|
|Cyclacel Pharmaceuticals Inc.||2,511,986,658.33%||-49.6%||-39.8%|
The Current Ratio of CRISPR Therapeutics AG is 8.3 while its Quick Ratio stands at 8.3. The Current Ratio of rival Cyclacel Pharmaceuticals Inc. is 7.6 and its Quick Ratio is has 7.6. CRISPR Therapeutics AG is better equipped to clear short and long-term obligations than Cyclacel Pharmaceuticals Inc.
CRISPR Therapeutics AG and Cyclacel Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Cyclacel Pharmaceuticals Inc.||0||0||0||0.00|
The consensus price target of CRISPR Therapeutics AG is $72, with potential upside of 8.55%.
Institutional & Insider Ownership
The shares of both CRISPR Therapeutics AG and Cyclacel Pharmaceuticals Inc. are owned by institutional investors at 46.8% and 16.2% respectively. Insiders owned roughly 0.4% of CRISPR Therapeutics AG’s shares. On the other hand, insiders owned about 13.53% of Cyclacel Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Cyclacel Pharmaceuticals Inc.||8.18%||45.73%||41.17%||7.93%||-30%||-1.65%|
For the past year CRISPR Therapeutics AG has 153.31% stronger performance while Cyclacel Pharmaceuticals Inc. has -1.65% weaker performance.
CRISPR Therapeutics AG beats on 8 of the 10 factors Cyclacel Pharmaceuticals Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The companyÂ’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the companyÂ’s oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.